Patients and methods: From 1992 to 1997, 247 stage I-II breast cancer patients, treated with conserving surgery, were treated at the National Cancer Institute of Genoa in a randomized study comparing the same CEF regimen delivered every two weeks (CEF14) or three weeks (CEF21). RT was applied to the residual breast at a total dose of 50 Gy in five weeks. Allowance was made for treatment at 2.3 Gy per fraction in order to compensate for gaps (hypofractionation). Radiotherapy DI was expressed as the average total dose received each week, i.e., 'weekly dose-rate' (WDR). The effect of various tumour, treatment and patient-related factors on the endpoint (a delivered WDR of RT < 9.5 Gy) was investigated by univariate analysis. Factors found to have /"-value =$ 0.20 were entered in multivariate analysis.
Introduction
Adjuvant chemotherapy has been shown to ameliorate survival rates in both premenopausal and postmenopausal breast cancer patients [1] . However, despite such an improvement, prognosis, particularly in some subsets, remains poor: the 10-year survival in node positive patients treated with polychemotherapy is 53% and 49%, for women under 50 and for those between 50 and 69, respectively. These results have prompted efforts to improve outcome by the investigation of new chemotherapy regimens, based on the use of new drugs or new strategies, such as the increase in dose or dose-intensity of cytotoxic drugs. Dose-intensity (DI) increase can be attained by different approaches: by increasing the doses of antineoplastic drugs (dose-escalation) or by reducing the interval between cycles, i.e. acceleration (dose-dense chemotherapy) [2] .
During chemotherapy-free breaks, regrowth of surviving tumour cells takes place. As corroborated by many animal studies and clinical observations, the regrowth is more rapid as cell numbers decrease [3, 4] . Since this is likely to be the setting of adjuvant chemotherapy for early breast cancer, such a growth can be limited if the time interval between schedules is kept as short as possible. This is the rationale of 'dose-dense' schedules where more drug per unit of time is administered [2] .
The same principles apply to radiotherapy as well. It is now recognized that regrowth of surviving clonogens during radiotherapy is a cause of treatment failure at least for certain tumour types [5] . Three trials in patients with head and neck tumours have prospectively validated the strategy of shortening overall time in order to reduce the opportunity of tumour cells to proliferate during treatment [6] [7] [8] .
Radiotherapy has a traditional local role after breast conserving surgery [9, 10] . In addition, two prospective phase III studies showed that radiotherapy against regional lymph nodes impacts survival [11, 12] . Radiotherapy and chemotherapy are likely to have an independent role since in these trials the effect of regional treatment was adjunctive to that of standard systemic therapy [11, 12] .
In such a situation chemotherapy and radiotherapy ideally should be started concomitantly soon after surgery, provided that chemotherapy does not enhance the local toxicity of radiotherapy and radiotherapy does not impact significantly on systemic (bone marrow) toxicity. Various authors have intensely debated this controversial point [13] [14] [15] .
A particular question raised by the introduction of dose-dense schedules is whether it is still feasible to deliver radiotherapy within the planned time. If decrease of chemotherapy duration jeopardizes radiotherapy duration, the overall strategy might fail.
From 1992 to 1997, we coordinated a multicenter phase III study evaluating the role of dose-dense chemotherapy strategy. All the patients undergoing breastconserving surgery were also treated with adjuvant local radiotherapy. The purpose of the present study is to investigate whether a dose-dense chemotherapy, i.e., chemotherapy administered at a shorter interval than the standard one, affects radiotherapy duration.
Patients and methods

Patient selection
From November 1992 to June 1997 the GONO-MIG (Gruppo Oncologico Nord Ovesl -Mammella Intergruppo) group carried out a phase III multicenter trial (GONO-MIG-1) evaluating the efficacy of a dose-dense chemotherapy regimen compared to the standard in 1,214 early breast cancer, patients (16) . Women with histologically proven breast cancer who had undergone radical mastectomy or breast conserving surgery plus full ipsilateral axillary node dissection, were eligible for the study if they had involved axillary nodes or were nodenegative but with high risk of recurrence. In node-negative patients the high risk was defined as the presence of at least one of the following criteria: age ^35 years, negative estrogen (ER) and progesteron receptor (PgR) status, tumour size >2 cm, poor histological grade (G3) or high proliferative rate determined by [ 3 H]thymidine labelling index. Other eligibility criteria included no clinical or radiological evidence of distant metastases, adequate bone marrow reserve (white blood cell count ^3,000/mm 3 , platelet count > 100,000/mm 3 ), adequate hepatic and renal function and surgery performed not more than five weeks before starting chemotherapy. The following were conditions for exclusion: age over 70 years, previous chemotherapy for cancer, pregnancy or lactation, postoperative regional radiotherapy except irradiation limited to the remaining breast after conservative surgery, previous or concomitant malignancy (except curatively treated skin or cervical carcinoma), any medical condition precluding anthracycline treatment or drug-requiring psychiatric illness.
The study was approved by the Protocol Review and Ethical Committees of the National Cancer Institute of Genoa, and by each collaborating center.
All patients enrolled by the National Cancer Institute of Genoa who had undergone conservative surgery (lumpectomy, segmental mastectomy) and complementary radiotherapy were eligible for the present analysis.
Treatment
After stratification by center, patients were randomly assigned, by telephone, to receive the standard adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide every 21 days (CEF-21), or the same chemotherapy every 14 days (CEF-14) plus G-CSF. In both arms chemotherapy was administered intravenously at the same doses (cyclophosphamide 600 mg/m 2 , epirubicin 60 mg/m 2 and 5-fluorouracil 600 mg/m 2 ) for six cycles. CEF-14 patients self-administered subcutaneous G-CSF at a dose of 5 ug/kg from day 4 to day 11, from cycles one to five. The planned duration of 6 cycles of chemotherapy was 70 and 105 days in CEF14 and CEF21 arms, respectively. The planned increase in dose-intensity was 50% in CEF14 arm as compared to CEF21.
Patients with ER positive tumours received tamoxifen 20 mg/day concurrently or starting at the end of chemotherapy.
Patients undergoing conservative surgery (lumpectomy, segmental mastectomy) were scheduled for treatment with complementary radiotherapy to the residual breast. Draining lymphatics outside the primary field were not to be treated. Radiotherapy had to be delivered through tangential fields to the residual breast at 2 Gy per fraction, five times per week (10 Gy/week) to the total dose of 50 Gy. However, allowance was made to compensate for short planned (gaps for holidays or machine maintenance) or unplanned gaps (such as those due to systemic toxicity or machine breakdown) by delivering 2.3 Gy per fraction four times per week (hypofractionation). In particular, short unplanned gaps during the second half of the week were corrected by delivering six 2 Gy fractions or four 2.3 Gy fractions and one 2 Gy fraction during the following week. The choice of hypofractionation and compensation for gaps was based upon physician attitude and preference. However, since there was some concern about the possible interaction between larger dose per fraction and chemotherapy, compensation for gaps was not usually strictly pursued in patients undergoing concomitant chemo-radiotherapy.
There were no coded criteria for radiotherapy discontinuation due to chemotherapy-related systemic toxicity. A boost dose to the surgical bed (10-15 Gy in five fractions of 2-3 Gy over one week) was given to patients considered at moderate or high risk of local failure (extensive Ss 25% intraductal component, positive surgical margins).
Chemotherapy had to start within five weeks from surgery. In the protocol, no directions were given regarding timing of chemotherapy and radiotherapy. Therefore, some patients received all the six cycles of chemotherapy before radiotherapy, while others had some overlap.
Statistics
Radiotherapy feasibility was expressed through the estimation of the number of patients receiving a total dose of radiotherapy within ±10% of that planned. Moreover, we also investigated the radiotherapy doseintensity expressed as the average total dose received each week, i.e., 'weekly dose-rate' (WDR).
For this latter endpoint we had to normalize total dose at 2 Gy per fraction. Without such a correction, we would have under-or overestimated WDR for patients treated at 2.3 Gy x 4/week (whole breast) or 3 Gy x 5/week (boost), respectively. In order to have an unbiased estimate of WDR, each single dose of 2.3 Gy to the whole breast was considered equivalent to 2.5 Gy, since it was delivered under the assumption that four fractions would have been equivalent to 10 Gy at 2 Gy per fraction. Thus, total dose to the whole breast was computed by substituting 2.3 with 2.5 Gy, while leaving other parameters unchanged.
For the boost phase, we assumed that each fraction always delivered 2 Gy independently from the actual dose delivered. This means that patients treated with 15 Gy in five fractions over one week during the boost phase were considered to have received 10 Gy in five fractions. For the purpose of the latter endpoint, which is to compare WDR between patients on an intention-to-treat basis, we believe that this is the correct approach, even if absolute considerations about WDR may be misleading.
Normalized total dose divided by treatment time (weeks) yielded WDR. In the present study an event is considered a WDR below 9.5 Gy/week, which is less than 95% of that planned.
The effect of the following factors on WDR was investigated by univariate analysis: age, menopausal status, co-morbidity, T-stage, N-stage, type of surgery, type of chemotherapy (CEF14 vs. CEF21), chemotherapy feasibility (number of cycles, treatment time and total dose), radiotherapy volume during tangentials, radiotherapy fractionation, radiotherapy boost, timing of chemotherapy-radiotherapy, type and grade of systemic toxicity. Chemotherapy and radiotherapy were considered as overlapping treatments if, for at least one cycle, both treatments were given on the same day. Co-morbidity was scored according to Kaplan-Feinstein [17] . Radiotherapy volume during tangential field irradiation was calculated by multiplying the length by the height by the width at midplane along the central axis. Skin toxicity was evaluated according to the EORTC scale. Systemic toxicity was graded according to WHO criteria.
Only bone marrow and mucosal toxicity along with nausea, fever and fatigue were considered as symptoms of 'systemic toxicity' because of the low number of patients showing toxicity of any other type.
Due to the paucity of patients with grade 2-4 myelotoxicity, grade 2-4 and 1 reactions were pooled. Similarly, patients with pT2 and pT4 lesions, those receiving less than six cycles of chemotherapy and those experiencing fever were pooled as well.
Data were treated categorically. Unless otherwise specified, median values were chosen as cut-off values.
The test of significance between proportions were done with the X 2 -test or Fisher's exact test as appropriate [18] , Factors found to have P-value ^ 0.20 were entered in multivariate analysis. Logistic regression was performed using standard techniques [19] .
Results
From 1992 to 1997, 370 patients were treated by our institution. A total of 267 patients with stage I-I I breast cancer underwent conserving surgery (lumpectomy, segmental mastectomy) and thus were treated with local radiotherapy as well. Of them, 20 were referred for radiotherapy at centers closer to their domicile and were excluded. Therefore the present analysis includes 247 patients fully treated at our institution.
Median age was 54 years (range: 29-71 years) and 96 patients (38.9%) were premenopausal. All patients had a performance status equal to 0 according to the ECOG system; co-morbidity (17) was as follows: grade 0, 212 patients (85.8%); grade 1, 27 patients (10.9%); grade 2, 6 patients (2.4%); grade 3, 2 patients (0.8%). Most of the patients had pTl (166 patients) or pT2 (76 patients) tumours; five additional patients were found to have T4 (pT4a: 1 patient; pT4b: 4 patients) tumours on pathology. Nodal negative and positive patients were equally distributed (124 and 123 patients, respectively). Most of the tumours were moderately differentiated (166 patients, 67.2%); 14 (5.7%) and 64 (25.9%) patients had Gl and G3 tumours, respectively. In three patients, grading was not assessable. Surgery consisted of segmental mastectomy in 51 patients (20.6%) and lumpectomy in 196 patients (79.4%).
Of 247 patients, 119 (48.2%) were randomized to the accelerated chemotherapy regimen (CEF14), while the remaining 128 (51.8%) to the standard duration schedule (CEF21).
One-hundred sixty-five patients (66.8%) completed the chemotherapy treatment as planned. A further 61 patients completed chemotherapy despite some violations. Thus, most of the patients (226, 91.5%) completed the six planned cycles of chemotherapy. Of those not completing, 5 refused the assigned treatment and 16 patients discontinued treatment for toxicity. Protocol violations were investigated relative to total dose/number of cycles and chemotherapy duration. Results were as follows: 201 patients (81.4%) received the total dose of chemotherapy within ±5% of that planned; regarding chemotherapy duration, 186 patients (75.3%) completed their assigned treatment within ±5% of planned duration. Bone marrow toxicity was different in the two arms. More patients in the accelerated arm suffered some grade of RBC toxicity (40% vs. 16%, P < 0.0001). However, the opposite was observed for WBC toxicity, with 33% and 17% of patients experiencing some grade of toxicity in the CEF21 and CEF14 arms (P -0.004), respectively. Platelet toxicity was not significantly different between the two arms.
Radiotherapy delivered a median nominal dose of 50 Gy (8.9-54 Gy) through tangentials. All but three patients (98.8%) received a cumulative total dose of radiotherapy within ± 10% of that planned. 121 patients (49.0%) were treated only at 2 Gy per fraction; in the remaining 126 patients (51%), the median number of 2.3 Gy fraction was 10 (range: 2-20). Four more patients were compensated throughout by giving six fractions per week. The use of hypofractionation was considered a surrogate for treatment compensation while being treated six times per week was not taken into account due to the small number of patients in this latter group (four patients).
A 10 Gy and 15 Gy boost to the surgical bed was delivered to 123 patients (49.8%) and 36 patients (14.6%), respectively. In most of the patients (142 patients, 57.5%) a direct orthovoltage (300 KW), 8 by 10 cm field was used to deliver the boost. In the remaining patients a proper energy electron field was employed. Median overall radiotherapy duration was 5.8 weeks (1-10.7); radiotherapy duration in patients who did not receive a boost dose was 4.86 (1-7.14) weeks.
Chemotherapy was always started before radiotherapy: 63 patients (25.5%) received sequential (chemotherapy before radiotherapy) chemoradiotherapy; in the remaining patients some overlap between chemotherapy and radiotherapy did occur (concurrent chemoradiotherapy). Details are reported in Table 1 . In the majority of patients, the overlap involved two cycles of chemotherapy. Radiotherapy most frequently started at the III cycle of chemotherapy, even though this was widely distributed. In 1994, because of evidence of unusual skin toxicity in three consecutive patients receiving accelerated chemotherapy and concomitant radiotherapy, it was decided to start radiotherapy after completion of chemotherapy in the CEF14 arm, and the protocol was amended accordingly. As a result, significantly more patients in the standard group (CEF21) had some over- lap between the two modalities (97% vs. 50%, P < 0.0001), although relatively more patients in the accelerated arm had more than two cycles of chemotherapy given during radiotherapy (27% vs. 12%, P = 0.002).
Median normalized total radiotherapy dose was 60 Gy (range 9.5-65 Gy). Median weekly dose rate was 10 Gy/wk (5.6-11.7). Fifty patients (20.2%) received a WDR < 9.5 Gy/wk.
The relationship between hypofractionation and other variables was further investigated. The concern about gap compensation in patients treated concomitantly resulted in significantly (P = 0.045) less patients being hypofractionated (87 of 184 patients, 47.3%) in this group than that of patients treated sequentially (39 of 63 patients, 61.9%). Since a higher percentage of patients in the CEF14 arm were treated sequentially, this resulted in more patients of the CEF14 arm (70 of 119 patients, 58.8%) than those of CEF21 arm (56 of 128 patients, 43.7%) being hypofractionated (P -0.017). However, after correcting for chemo-radiotherapy timing, the difference in treatment compensation between treatment arms disappeared. In particular, after selecting only patients with some overlap of chemotherapy and radiotherapy (184 patients), the probability of being hypofractionated was 53% and 44% in CEF14 and CEF21 arms, respectively (P = 0.25).
At univariate analysis ( Table 2 ) the probability of WDR < 9.5 Gy/wk significantly associated with age (P = 0.001); menopausal status (P = 0.006); a high number of cycles of chemotherapy overlapping with radiotherapy (P = 0.003); the development of leukopenia (P = 0.047). A trend towards an increased probability of a suboptimal WDR was found for patients receiving a radiotherapy boost (P = 0.055) and for those experiencing RBC toxicity (P = 0.053). On the other hand a treatment at 2.3 Gy per fraction was associated with a higher probability of receiving a WDR > 9.5 (P = 0.017). The type of treatment (CEF14 vs. CEF21) did not affect the probability of WDR < 9.5 Gy/wk (P = 0.77).
At multivariate analysis, age (P -0.0003), radiotherapy fractionation (P = 0.017) and WBC toxicity (P = 0.027) were independent predictors of WDR < 9.5 Gy (Table 3) . Moreover, a number of chemotherapy cycles overlapping with RT greater than two was associated with an increased risk of radiotherapy delay (P = 0.0063). A borderline effect was also found for RBC toxicity (P = 0.10).
Discussion
Chemotherapy and radiotherapy have a complementary role as adjuvant treatments of early breast cancer. Chemotherapy aims mainly at preventing distant metastases although a locoregional role has been reported [20] ; on the other hand, radiotherapy has a loco-regional effect, although recent data confirm that both local [21] and regional [11, 12] treatments impact distant metastasis rate. Timing of the two modalities is controversial. Ideally, the earlier, concomitant administration of both treatments would be preferable, provided that they do not negatively interact. Despite initial observations [22] , it is unlikely that radiotherapy hampers chemotherapy feasibility and its dose intensity, even when regional nodes are part of the target [23] . On the other hand, it is also unlikely that chemotherapy enhances local toxicity of radiotherapy if drugs cross-reacting with X-rays are avoided at least within standard chemotherapy schedules [24] .
Few data are available about RT feasibility when a dose-dense schedule of chemotherapy is introduced. In particular we focused on treatment time of radiotherapy, in consideration of the fact that, since a time factor is hypothesized for chemotherapy, this may be the case for radiotherapy as well. Data obtained in locally advanced breast cancer cells with 3H-thymidine labeling index before and after neoadjuvant chemotherapy show that 19%-36% of patients with low proliferating tumours undergo acceleration after treatment with chemotherapy [25] [26] [27] . Moreover, between 28% and 47% of patients with rapidly proliferating tumours remain in the 'high category' after chemotherapy despite the fact that primary chemotherapy is expected to act preferentially on rapid tumours [28] . Based on these data, we cannot exclude that if chemotherapy impacts radiotherapy feasibility by elongating its duration, the rationale of the whole approach may be diminished.
The results reported here show that there is no direct effect of chemotherapy duration on radiotherapy feasibility in terms of both total dose and elapsed treatment weeks.
In our experience, compliance with postoperative local radiotherapy was correlated to age and chemotherapy-radiotherapy timing. Older patients are less likely to be compliant. Similarly, patients receiving more than two cycles of chemotherapy during radiotherapy are also at risk of discontinuing radiotherapy. We believe that this finding merely reflects a higher probability of suffering chemotherapy-related complications, which in turn can interfere with radiotherapy. This consideration is also supported by the significant impact of WBC toxicity on WDR and the borderline effect of RBC toxicity. In this regard, it should be noted that the accelerated arm was associated with an increased frequency of overlap > 2 cycles between chemotherapy and radiotherapy and with a higher rate of RBC toxicity; however, because of the concomitant administration of G-CSF, WBC toxicity was higher in the conventional chemotherapy arm. Thus, we can reasonably exclude that chemotherapy duration has an indirect impact (through systemic toxicity) upon radiotherapy feasibility as well.
Our experience may be different from that of other centers since we did not attempt to force radiotherapy in the presence of chemotherapy-related complications.
Our findings are not surprising. However, apart from age, systemic toxicity, and chemoradiotherapy overlap, two other findings deserve some comments.
First, hypofractionation was shown to be an effective way to compensate for short gaps. It remains to be investigated whether it is associated with a detectable increase in toxicity on late responding tissues when used sporadically. Secondly, contrary to certain expectations, no correlation was found between skin toxicity and WDR at multivariate analysis. Which factors are associated with skin toxicity in these patients will be the subject of a future investigation.
In conclusion, chemotherapy can be accelerated without jeopardizing radiotherapy feasibility. Whether this is clinically relevant to outcome, awaits data maturation.
